N-acetylcysteine reduces severity and mortality in COVID-19 patients: A systematic review and meta-analysis

• Published in: Journal of advanced veterinary and animal research 2023-06, Vol.10 (2), p.157-168
• Main Authors: Alam, Mohammad Shah, Hasan, Mohammad Nazmol, Maowa, Zannatul, Khatun, Fahima, Nazir, K H M Nazmul Hussain, Alam, Mohammad Zahangeer
• Format: Article
• Language: English
• Subjects: Acetylcysteine; Antioxidants; C-reactive protein; Clinical outcomes; Coronaviruses; COVID-19; COVID-19 vaccines; Cytokine storm; Dimers; Disease prevention; Disease transmission; Infections; Length of stay; Meta-analysis; Mortality; n-acetylcysteine; covid-19; sarscov-2; severity; mortality; treatment; Neutrophils; Original; Oxidative stress; Oxygen content; Oxygen saturation; Oxygenation; Pathogenesis; Placebos; Pneumonia; Proteins; Search engines; Sepsis; Severe acute respiratory syndrome coronavirus 2; Systematic review; Thrombosis; Tumor necrosis factor-TNF; Viral diseases
• ISSN: 2311-7710; 2311-7710
• DOI: 10.5455/javar.2023.j665

Recent clinical studies suggest that oxidative stress is one of the key players in the pathogenesis of coronavirus disease 2019 (COVID-19), and N-acetylcysteine (NAC), a potent antioxidant, has been shown to improve clinical outcomes in COVID-19 patients. We conducted a systematic review and meta-analysis of the literature published on the therapeutic intervention of NAC on COVID-19 infection. We searched PubMed, Google Scholar, and Science Direct. We identified and screened eight studies with 20,503 participants, including 2,852 in the NAC-treated group and 17,651 in the placebo group, which reported the effect of NAC on COVID-19 infection. A meta-analysis was performed using forest plots under fixed effect estimates based on the standardized mean difference (SMD) and risk ratio (RR). Pooled analysis showed that NAC was associated with lower mortality in patients with COVID-19 compared with the placebo group [RR, 0.65; (95% CI: 0.56 to 0.75); < 0.0001]. Similarly, C-reactive protein (CRP) [SMD, -0.32; (95% CI: -56 to -0.09); = 0.0070] and D-dimer [SMD, -0.35, (95% CI: -0.59 to -0.10; 0.0062] levels were significantly decreased, and the oxygenation marker, PaO /FiO ratio, was increased in the NAC-treated group compared with the placebo group [SMD, 0.76; (95% CI: 0.48 to 1.03); < 0.0001]. Although the number of included studies was minimal, this meta-analysis suggests that NAC may have a positive effect on COVID-19 outcomes, specifically, a significant decrease in CRP and D-dimer levels and a significant increase in oxygen saturation, which decreased mortality. We have also presented a comprehensive review of the role and mechanisms of NAC in patients with COVID-19.